Hassan clarified reports that Vytorin accounts for 70% of the company's earnings. He said they are not accurate because they don't take into account Schering's recent big acquisition of Organon BioSciences.
Finally, Hassan said that he said his industry will continue to be very strong regardless of the outcome of November's general election. "People will always want new and innovative drugs and treatments," he said.
Cramer told a viewer that Brocade (BRCD ) blew the quarter and he's now a seller of the company. He admitted he was "wrong" about the company.